Gilteritinib

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Renal Impaired

Conditions

Renal Impaired, Gilteritinib, Normal Renal Function, Pharmacokinetics of ASP2215

Trial Timeline

Jan 28, 2021 → Jul 18, 2022

NCT ID

NCT04699877

About Gilteritinib

Gilteritinib is a phase 1 stage product being developed by Astellas Pharma for Renal Impaired. The current trial status is completed. This product is registered under clinical trial identifier NCT04699877. Target conditions include Renal Impaired, Gilteritinib, Normal Renal Function.

What happened to similar drugs?

20 of 20 similar drugs in Renal Impaired were approved

Approved (20) Terminated (0) Active (0)

✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved

✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved

✅Tacrolimus, Prograf®Astellas PharmaApproved

✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved

✅Tacrolimus + CyclosporineAstellas PharmaApproved

✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03409081	Pre-clinical	Completed	—	—	Acute Myeloid Leukemia (AML)
NCT03070093	Pre-clinical	Completed	—	—	Acute Myeloid Leukemia (AML)
NCT07140016	Phase 1	Recruiting	Sep 22, 2025	Dec 31, 2029	Non-small Cell Lung Cancer (NSCLC)
NCT06734585	Pre-clinical	Completed	Jan 9, 2025	Jul 14, 2025	Acute Myeloid Leukemia
NCT04699877	Phase 1	Completed	Jan 28, 2021	Jul 18, 2022	Renal Impaired
NCT02561455	Phase 1/2	Completed	May 3, 2016	Jul 28, 2020	Advanced Solid Tumors
NCT02181660	Phase 1	Completed	Jun 16, 2014	Jun 27, 2016	Acute Myeloid Leukemia (AML)

Competing Products

20 competing products in Renal Impaired

See all competitors

Product	Company	Stage	Hype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109	MBX Biosciences	Phase 1	23
LY3473329	Eli Lilly	Phase 1	29
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
SPR001	Spruce Biosciences	Phase 2	25
SPR001	Spruce Biosciences	Phase 2	25
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
Tildacerfont	Spruce Biosciences	Phase 2	17
Drotrecogin alfa activated (Xigris)	Eli Lilly	Phase 2	35
LY3819469	Eli Lilly	Phase 1	29
Atezolizumab + Cabozantinib	Chugai Pharmaceutical	Phase 3	32
DS-6000a + DS-6000a	Daiichi Sankyo	Phase 1	33
DS-1093a	Daiichi Sankyo	Phase 1	29
CS-3150	Daiichi Sankyo	Phase 3	40
AGS-16C3F	Astellas Pharma	Phase 1	29
AGS-16M8F	Astellas Pharma	Phase 1	29
CP-461	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
YM178	Astellas Pharma	Phase 1	29
intravenous immunoglobulins (IVIG)	Astellas Pharma	Phase 1	29
bixalomer	Astellas Pharma	Pre-clinical	26